Article Data

  • Views 815
  • Dowloads 138

Original Research

Open Access

Measurement of serum interleukin 17 level in patients with genital warts before and after intralesional tuberculin injection

  • Mohamed Azab1,*,
  • Mohamed M. El-Shabrawy2
  • Essam R. O. Abu Nafea3
  • Hesham A. Nada4

1Department of Andrology, Sexology and STDS, Faculty of Medicine, Suez Canal University, 41511 Ismailia, Egypt

2Department of Clinical pathology, Faculty of Medicine, Suez Canal University, 41511 Ismailia, Egypt

3Department of Dermatology and Venereology, Dermatology and leprosy Mansoura Hospital, Ministry of health and population, 11049 Mansoura, Egypt

4Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Suez Canal University, 41511 Ismailia, Egypt

DOI: 10.31083/jomh.2021.104 Vol.18,Issue 1,January 2022 pp.1-7

Submitted: 28 May 2021 Accepted: 03 August 2021

Published: 31 January 2022

*Corresponding Author(s): Mohamed Azab E-mail: Dr.Mohamed_azab@yahoo.com

Abstract

Introduction and aim: Genital wart infection is a distressing sexually transmitted infection that causes marked fear and stress to both males and females. Tuberculin Purified protein derivative (PPD) injection is an upcoming safe and effective modality for the treatment of genital warts. Interleukin 17 (IL-17) was found to be lower in wart patients than controls. This study aimed at measurement of serum level of IL-17 in genital warts patients before and after PPD injection.

Patients and methods: The study was carried out as case-control interventional study on 63 patients (37 males and 26 females) with genital warts attending Dermatology and Andrology Clinics, faculty of medicine, Suez Canal University hospitals. 50 controls were enrolled in the study. All patients have injected 10 tuberculin units of PPD intradermally in the mother or largest warts every 2 weeks till 6 sessions. Serum level of IL-17 was measured by Sandwich ELISA technique to all patients before and after PPD injection and to all control subjects.

Results: The mean age of patients was 30.8 years, the mean duration of warts was 4.73 months, the mean number of warts was 9.76 warts and 14.3% of patients experienced side effects to PPD. (58.7%) of patients were completely recovered from warts. Mean serum IL-17 was 81.1 ± 64.2 pg/mL versus 118.9 ± 93.8 pg/mL in genital wart patients versus controls respectively (P < 0.05) and 81.1 ± 64.2 pg/mL versus 107.1 ± 66.8 pg/mL before and after PPD injection respectively (P < 0.05).

Conclusion: IL-17 serum level was significantly lower in genital wart patients than normal controls. IL-17 serum level had been increased significantly after PPD intralesional injection than pretreatment levels and significantly related to clinical response to PPD. IL-17 suggested having a role in the clinical efficacy of PPD in the treatment of genital warts.

Keywords

Genital warts; Tuberculin PPD; Interleukin 17

Cite and Share

Mohamed Azab,Mohamed M. El-Shabrawy,Essam R. O. Abu Nafea,Hesham A. Nada. Measurement of serum interleukin 17 level in patients with genital warts before and after intralesional tuberculin injection. Journal of Men's Health. 2022. 18(1);1-7.

References

[1] Leslie SW, Kumar S. Genital Warts. In StatPearls. Treasure Island (FL): StatPearls Publishing. 2019.

[2] Leung AK, Barankin B, Leong KF, Hon KL. Penile warts: an update on their evaluation and management. Drugs Context. 2018; 7: 212563.

[3] Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sexually Transmitted Diseases. 1993; 20: 344–345.

[4] Baigrie D, Qafiti FN, Buicko JL. Electrosurgery. In StatPearls. Treasure Island (FL): StatPearls Publishing. 2020.

[5] On SC, Linkner RV, Haddican M, Yaroshinsky A, Gagliotti M, Singer G, et al. A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts. Journal of drugs in dermatology. 2014; 13: 1400–1405.

[6] Jung JM, Jung CJ, Lee WJ, Won CH, Lee MW, Choi JH, et al. Topically applied treatments for external genital warts in nonimmunocompro-mised patients: a systematic review and network meta‐analysis. British Journal of Dermatology. 2020; 183: 24–36.

[7] Choi H. Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? An exploratory study. International Brazilian Journal of Urology. 2019; 45: 361–368.

[8] Singh M, Thakral D, Kar HK, Rishi N, Sharma PK, Mitra DK. Distinct clinico-immunological profile of patients infected with human papilloma virus genotypes 6 and 11. VirusDisease. 2017; 28: 200–204.

[9] Mohamed EEM, El Taieb MA, Abd El- sabour GA. Intralesional Vitamin D3 versus Purified Protein Derivatives in the Treatment of Multiple Cutaneous Warts: Comparative Study. The Egyptian Journal of Hospital Medicine. 2019; 76: 3589–3594.

[10] Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. The Journal of Allergy and Clinical Immunology. 2013; 130: 1030–1048.

[11] Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine. 2013; 62: 175–182.

[12] El-Hamd MA, Assaf HA, Nada EA. Possible role of interleukin-17 and macrophage migration inhibitory factor in cutaneous warts. Journal of Cosmetic Dermatology. 2019; 17: 1250–1253.

[13] Ghanem AH, Esawy AM, Khalifa NA, Kamal HM. Evaluation of serum interleukin 17 and zinc levels in recalcitrant viral wart. Journal of Cosmetic Dermatology. 2020; 19: 954–959.

[14] Nayak S, Acharjya B. Mantoux test and its interpretation. Indian Dermatology Online Journal. 2012; 3: 2–6.

[15] Choudhary D, Piya S. Treatment of Warts by Immunotherapy using Purified Protein Derivative. Birat Journal of Health Sciences. 2018; 3: 463–467.

[16] Sendagorta-Cudós E, Burgos-Cibrián J, Rodríguez-Iglesias M. Genital infections due to the human papillomavirus. Enfermedades Infecciosas Y Microbiologia Clinica. 2019; 37: 324–334.

[17] Lynch MD, Cliffe J, Morris-Jones R. Management of cutaneous viral warts. British Medical Journal. 2014; 348: g3339.

[18] Nimbalkar A, Pande S, Sharma R, Borkar M. Tuberculin purified protein derivative immunotherapy in the treatment of viral warts. Indian Journal of Drugs in Dermatology. 2016; 2: 19.

[19] Rajashekar TS, Amulya R, Sathish S, Kumar S. Comparative study of intralesional BCG and PPD in the treatment of multiple cutaneous warts. Indian Journal of Clinical and Experimental Dermatology. 2018; 2018: 1–6.

[20] Eassa BI, Abou-Bakr AA, El-Khalawany MA. Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women. Dermatologic Therapy. 2011; 24: 137–143.

[21] Mohamed EEM, El Taieb MA, Abd El- sabour GA. Intralesional Vitamin D3 versus Purified Protein Derivatives in the Treatment of Multiple Cutaneous Warts: Comparative Study. The Egyptian Journal of Hospital Medicine. 2019; 76: 3589–3594.

[22] Shaheen MA, Salem SAM, Fouad DA, El-Fatah AAA. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: a comparative clinical and immunological study. Dermatologic Therapy. 2016; 28: 194–200.

[23] Abd-Elazeim FMA, Mohammed GFA, Fathy A, Mohamed RW. Evaluation of IL-12 serum level in patients with recalcitrant multiple common warts, treated by intralesional tuberculin antigen. The Journal of Dermatological Treatment. 2014; 25: 264–267.

[24] Elela I, Elshahid AR, Mosbeh AS. Intradermal vs intralesional purified protein derivatives in treatment of warts. The Gulf Journal of Dermatology and Venereology. 2011; 18: 21–26.

[25] Youssef SS, Diab H, Sallam MN, Ahmed A. Evaluation of IL-2, IFN-gamma mRNA gene expression in resistant genital and plantar warts, treated by intralesional tuberculin. Pan Arab League of Dermatologists. 2009; 20: 147–158.

[26] Kus S, Ergun T, Gun D, Akin O. Intralesional tuberculin for treatment of refractory warts. Journal of the European Academy of Dermatology and Venereology. 2005; 19: 515–516.

[27] Nofal A, Soliman M, Hamdy F, Alakad R. Intralesional Candida antigen versus intralesional tuberculin in the treatment of recalcitrant genital warts: a comparative study. Journal of the American Academy of Dermatology. 2020; 82: 1512–1514.

[28] Mareti Bonin C, Zatorre Almeida-Lugo L, Rodrigues dos Santos A, Tezelli Junqueira Padovani C, Silva Pina AF, Teixeira Ferreira AM, et al. Interleukin-17 expression in the serum and exfoliated cervical cells of patients infected with high-risk oncogenic human papillomavirus. Cytokine. 2019; 120: 92–98.

[29] Maronn M, Salm C, Lyon V, Galbraith S. One-year experience with candida antigen immunotherapy for warts and molluscum. Pediatric Dermatology. 2008; 25: 189–192.

[30] Nofal A, Nofal E, Yosef A, Nofal H. Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach. International Journal of Dermatology. 2015; 54: 667–671.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus CiteScore 0.7 (2021) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).

Submission Turnaround Time

Conferences

Top